Tenderwize
Zurück zur Suche

Ibuprofen 400 mg and 600 mg (prescription, non-retarded)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Mar 30, 2027 · 216 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Ibuprofen (ATC: M01AE01 - verschreibungspflichtig, in nicht retardierter Darreichungsform mit den Wirkstärken 400mg und 600mg)

55/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

55 / 100

Komplexität

20 / 100

Risikofaktoren

No volume commitment; the agreement only provides a framework for discounts but does not guarantee any sales.

This is not a public procurement under EU law. Legal protection mechanisms (e.g., suspension periods) are only cited vo...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Supply of Ibuprofen 400 mg and 600 mg prescription-only non-retarded finished medicinal products under non-exclusive discount agreements
  • Contracting with the statutory health insurance fund AOK Sachsen-Anhalt
Vollständige Zusammenfassung anzeigen

This is a non-exclusive open-house model for discount agreements under German social law (§130a SGB V) for Ibuprofen 400mg and 600mg (prescription, non-retarded). Any eligible pharmaceutical company can join at any time until 31 March 2027, with contracts starting from 1 June 2025 and lasting maximum 24 months (until 31 May 2027). The publication is voluntary for transparency; it is not a public procurement under EU law. No estimated value is stated, and no award criteria weights are provided. Submission is mainly by post, but electronically signed PDFs via email are also accepted.

Risiken

No volume commitment; the agreement only provides a framework for discounts but does not guarantee any sales.

This is not a public procurement under EU law. Legal protection mechanisms (e.g., suspension periods) are only cited vo...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • No exclusivity; each qualifying company gets a contract on identical terms
  • Contract period: max 24 months, ends 31 May 2027, starting no earlier than 1 June 2025

Eligibility

  • Eligible: any pharmaceutical company or consortium that meets participation requirements under §130a SGB V

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

No award criteria specified; all eligible companies are accepted without competition.

Auftraggeber

Ort

Magdeburg, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE258393558

Tätigkeit

Health

Lose (1)

LOT-0001

Ibuprofen 400 mg and 600 mg (prescription, non-retarded)

Non-exclusive discount agreements for Ibuprofen finished medicinal products with active substance Ibuprofen (ATC M01AE01) in strengths 400mg and 600mg, prescription-only, non-retarded form. Open to all qualifying pharmaceutical companies. No exclusivity. Contract duration max 24 months from earliest start 01.06.2025 to 31.05.2027.

SuppliesEU fundedElectronic submission

Ort

DEE03, Germany

Dauer

2 YEAR

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria specified; all eligible companies are accepted without competition.

Frist

Deadline Mar 30, 2027

Vergabedetails

Veröffentlichungsdatum
09 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
233889-2025

Dokumente (1)

Ähnliche Ausschreibungen